Cost-effectiveness of the Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults - PubMed (original) (raw)

Cost-effectiveness of the Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults

Phuc Le et al. JAMA Intern Med. 2018.

Abstract

Importance: The live attenuated herpes zoster vaccine (ZVL) is recommended for immunocompetent adults 60 years or older, but the efficacy wanes with age and over time. A new adjuvanted herpes zoster subunit vaccine (HZ/su) has higher efficacy but might be more expensive. The choice of vaccines depends on their relative values.

Objective: To assess the cost-effectiveness of HZ/su.

Design, setting, and participants: Markov decision model with transition probabilities based on the US medical literature. Participants were immunocompetent adults 60 years or older. Data were derived from participant groups ranging in number from less than 100 to more than 30 000 depending on the variable assessed. The study dates were July 1 to 31, 2017.

Exposures: No vaccination, ZVL (single dose), and HZ/su (2-dose series) vaccine administered at different ages.

Main outcomes and measures: Total costs and quality-adjusted life-years (QALYs) were estimated.

Results: Based on randomized clinical trial data, at a price of 280perseries(280 per series (280perseries(140 per dose), HZ/su was more effective and less expensive than ZVL at all ages. The incremental cost-effectiveness ratios compared with no vaccination ranged from 20038to20 038 to 20038to30 084 per QALY, depending on vaccination age. The finding was insensitive to variations in most model inputs other than the vaccine price and certain combinations of low adherence rate with a second dose and low efficacy of a single dose of HZ/su. At the current ZVL price ($213 per dose), HZ/su had lower overall costs than ZVL up to a price of 350per2−doseseries.Inprobabilisticsensitivityanalysis,HZ/suhad73350 per 2-dose series. In probabilistic sensitivity analysis, HZ/su had 73% probability of being cost-effective for 60-year-olds at 350per2−doseseries.Inprobabilisticsensitivityanalysis,HZ/suhad7350 000 per QALY.

Conclusions and relevance: Under conservative assumptions, at a price of 280perseries(280 per series (280perseries(140 per dose), HZ/su would cost less than ZVL and has a high probability of offering good value.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: None reported.

Figures

Figure 1.

Figure 1.. Tornado Diagram of the Incremental Cost-effectiveness Ratio (ICER) of the Adjuvanted Herpes Zoster Subunit Vaccine (HZ/su) at Vaccination Age of 60 Years

Ranges are in parentheses, with the left values leading to the leftmost ICERs. BOI indicates burden of illness; HZ, herpes zoster; PHN, postherpetic neuralgia; QALY, quality-adjusted life-year; and ZVL, live attenuated herpes zoster vaccine. ICER values are given in 2016 US dollars. aRanges for these age-specific parameters are listed in Table 1, with the highest values leading to the leftmost ICERs. bIncidences in both men and women were varied at the same time with ranges listed in Table 1.

Figure 2.

Figure 2.. Two-Way Sensitivity Analysis at Vaccination Age of 60 Years With a Willingness-to-Pay Threshold of $50 000 per Quality-Adjusted Life-year

A-C, Letter x denotes base case. HZ/su indicates adjuvanted herpes zoster subunit vaccine; ZVL, live attenuated herpes zoster vaccine. Costs are given in 2016 US dollars.

Figure 3.

Figure 3.. Probability of Each Strategy Being Cost-effective at Different Willingness-to-Pay Thresholds

A-C, Probabilistic sensitivity analysis. HZ/su indicates adjuvanted herpes zoster subunit vaccine; QALY, quality-adjusted life-year; and ZVL, live attenuated herpes zoster vaccine. Costs are given in 2016 US dollars.

Comment in

Similar articles

Cited by

References

    1. Morrison VA, Johnson GR, Schmader KE, et al. ; Shingles Prevention Study Group . Long-term persistence of zoster vaccine efficacy. Clin Infect Dis. 2015;60(6):900-909. - PMC - PubMed
    1. Oxman MN, Levin MJ, Johnson GR, et al. ; Shingles Prevention Study Group . A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352(22):2271-2284. - PubMed
    1. Schmader KE, Levin MJ, Gnann JW Jr, et al. . Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years. Clin Infect Dis. 2012;54(7):922-928. - PMC - PubMed
    1. Schmader KE, Oxman MN, Levin MJ, et al. ; Shingles Prevention Study Group . Persistence of the efficacy of zoster vaccine in the Shingles Prevention Study and the Short-Term Persistence Substudy. Clin Infect Dis. 2012;55(10):1320-1328. - PMC - PubMed
    1. Lal H, Cunningham AL, Godeaux O, et al. ; ZOE-50 Study Group . Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015;372(22):2087-2096. - PubMed

MeSH terms

Substances

LinkOut - more resources